Home Business Eli Lilly Earnings In Line With Estimates, Hershey Edges Out For EPS

Eli Lilly Earnings In Line With Estimates, Hershey Edges Out For EPS

Eli Lilly and Co (NYSE:LLY) and Hershey Co (HSY) released the results from their first quarters before opening bell this morning. Eli Lilly’s results were in line with consensus on earnings but missed on revenues. The drug maker reported non-GAAP earnings of 70 cents per share on revenue of $4.68 billion. Analysts had been expecting $4.78 billion in revenue. Reported earnings per share were 68 cents.

Hershey Co (NYSE:HSY) edged out earnings estimates, coming in at $1.14 per share in diluted earnings on $1.87 million in revenue, which missed estimates. Analysts had been expecting the chocolate maker to report $1.15 per share in earnings on $1.9 million in revenue. Adjusted earnings per share were $1.15.

Breaking down Eli Lilly’s results

According to this morning’s release, Eli Lilly and Co (NYSE:LLY)’s revenue fell 16% because of patent expirations for the fibromyalgia and depression drug Cymbalta and the osteoporosis drug Evista in the U.S. Strong volume growth internationally partially offset that decline.

Eli Lilly and Co (NYSE:LLY) revised its earnings per share guidance for the full year, adjusting reported  earnings projections to be between $2.70 and $2.78 per share and non-GAAP earnings to be between $2.72 and $2.80 per share.

Eli Lilly and Co (NYSE:LLY) provided a number of updates on new drugs as well. The FDA approved cancer drug Cyramza to be used once for patients with certain types of cancer. The drug maker received a patent with its partner Boehringer Ingelheim to combine two drugs to treat type 2 diabetes. Eli Lilly also saw positive results for its trials of the lung cancer drug Revel and type 2 diabetes drug Award.

Breaking down Hershey’s results


Hershey Co (NYSE:HSY)’s reported a 1.4% increase in retail takeaway for the 12 weeks ending March 22, which excluded Easter holiday shopping. Adjusted gross margin fell 10 basis points. CMG market share, including Easter activity last year, fell .1 points. Market share in non-chocolate U.S. candy, mint and gum increased but was offset by the expected decline in share of chocolate because of the timing of new product launches and advertising and consumer marketing.

Hershey Co (NYSE:HSY) also reaffirmed its previous guidance for the full 2014 fiscal year. The company expects a 5% to 7% increase in net sales, mostly due to volume. Hershey expects reported diluted earnings per share to be between $3.99 and $4.08 per share. The company projects adjusted earnings to rise by between 9% and 11% and be between $4.05 and $4.13 per share.